Yahoo Finance

• Total Revenue: $8.6 million for Q1 2025, a 9% increase from the same period in 2024.

• Ameluz Sales Increase: $0.5 million increase due to higher unit price and RotoLED XL lamp launch.

• Total Operating Expenses: $13.1 million for Q1 2025, down from $13.4 million in Q1 2024.

• Cost of Revenues: $3.1 million for Q1 2025, a 22.1% decrease from the prior year.

• SG&A Expenses: Decreased by $0.6 million or 6.5% compared to Q1 2024.

• R&D Expenses: Increased by $1.2 million due to assumption of clinical trial activities for Ameluz.

• Net Loss: $4.2 million or $0.47 per share for Q1 2025, compared to $10.4 million or $2.88 per share in Q1 2024.

• Adjusted EBITDA: Increased to $4.4 million for Q1 2025 from $4.6 million in Q1 2024.

• Cash and Cash Equivalents: $1.8 million as of March 31, 2025, down from $5.9 million as of December 31, 2024.

• Inventory: $6.5 million as of March 31, 2025, compared to $6.6 million as of December 31, 2024.

• Warning! GuruFocus has detected 5 Warning Signs with BFRI.

Release Date: May 16, 2025

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

Positive Points

• Biofrontera Inc (NASDAQ:BFRI) reported a 9% increase in total revenues for the first quarter of 2025, reaching $8.6 million.

• The company successfully reduced its cost of revenue and operating costs compared to the same period in the previous year.

• A new formulation of Ameluz, free from the allergen propylene glycol, has been granted a patent, providing protection until December 2043.

• Biofrontera Inc (NASDAQ:BFRI) achieved key milestones in clinical trials, including the final patient enrollment for a Phase 3 trial of Ameluz for actinic keratosis and completion of a one-year follow-up for basal cell carcinoma treatment.

• The company increased its EBITDA and gross profit, supporting its goal of reaching breakeven quickly.

Negative Points

• Biofrontera Inc (NASDAQ:BFRI) reported a net loss of $4.2 million for the first quarter of 2025, although this was an improvement from the previous year's loss.

• The company experienced a decrease in cash and cash equivalents, dropping to $1.8 million as of March 31, 2025, from $5.9 million at the end of 2024.

• Research and development expenses increased by $1.2 million compared to the previous year, driven by the assumption of all clinical trial activities for Ameluz in the United States.

• Legal expenses increased by $1.2 million due to patent claims, partially offsetting savings in other areas.

• The sales force experienced some turnover, and the company is working on restructuring its commercial team to improve efficiency.